Please provide your email address to receive an email when new articles are posted on . The deep learning system demonstrated an AUC of 0.97, a sensitivity of 91.1%, a specificity of 93.4% and an ...

Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay News — ...

Gail Cairns started experiencing sight loss, headaches, and eye pain, but did not go to an optician when she first had ...

Ischemic optic neuropathies are the most common acute optic nerve pathology in patients older than 50 years of age. A 62-year-old Asian man presents to the emergency department with a complaint of ...

Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch ...

Oculis Holding AG (OCS) shares ended the last trading session 6.3% higher at $21.13. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Novo Nordisk faces a suit claiming it failed to warn users of Ozempic of the danger of blindness. The suit is brought by a Maryland man who developed non-arteritic anterior ischemic optic neuropathy ...

Privosegtor is Oculis ' second ophthalmic drug to start a pivotal trials programme after OCS-01, a topical anti-TNF drug in ...

Privosegtor (also known as OCS-05) is a “first-in-class peptoid small molecule” for neuroprotective therapy for acute optic ...

Researchers found that among semaglutide users, the incidence rate of nonarteritic anterior ischemic optic neuropathy was 14.5 per 100,000 person-years. HealthDay News — For individuals with type 2 ...

Primary care and emergency medicine clinicians should familiarize themselves with common ophthalmologic conditions that, with timely referral and treatment, may help to improve vision. Ischemic optic ...

Increased risk for NAION seen among participants with T2D, overweight/obesity receiving semaglutide versus non-GLP1-RA meds. (HealthDay News) — Semaglutide is associated with nonarteritic anterior ...